Why Endocyte (ECYT) Stock Is Declining Today

NEW YORK (TheStreet) -- Endocyte (ECYT) - Get Endocyte, Inc. Report shares are down 6.4% to $6.54 on Tuesday after Brean Capital downgraded the stock to "hold" from "buy".

The downgraded outlook stems from the firm's belief that the biotech company's investigational target cancer therapeutic treatment, Vintafolide, will only produce marginal returns for the company.STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

ECYT

Scroll to Continue

TheStreet Recommends

MARKETS

VMWAVGODELL

VMware Stock Surges On Reports of Potential $50 Billion Broadcom Takeover

3 hours ago

MARKETS

TSLA

Tesla Stock Slips Lower On Report Of More Shanghai Factory Production Delays

2 hours ago

MARKETS

SBUXMCD

Starbucks Exits Russia Market, Following McDonald's, As War Against Ukraine Rages On

7 minutes ago

data by

YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.